Uncategorized

Thoughts from Geoff Meyerson This past two weeks I had the privilege of visiting Japan and China, hosted by Locust […]

Podcast: Play in new window | Download (Duration: 7:34 — 17.3MB)

Subscribe: Apple Podcasts | Spotify | RSS

During the Asia-focused Episode 29 of Biotalk, Geoff shares insights into key trends and developments shaping the biotech landscapes in

Podcast: Play in new window | Download (Duration: 17:28 — 40.0MB)

Subscribe: Apple Podcasts | Spotify | RSS

During Episode 28 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2025 Q2 Report: Global Trends in Biopharma

Podcast: Play in new window | Download (Duration: 7:47 — 17.8MB)

Subscribe: Apple Podcasts | Spotify | RSS

During Episode 27 of Biotalk, Geoff Meyerson, CEO of Locust Walk, steps back to examine the macro forces shaping the

Podcast: Play in new window | Download (Duration: 10:38 — 24.3MB)

Subscribe: Apple Podcasts | Spotify | RSS

During the Asia-focused Episode 26 of Biotalk, Geoff Meyerson, CEO of Locust Walk, shares fresh insights from Japan, China, and Korea,

Podcast: Play in new window | Download (Duration: 13:17 — 30.4MB)

Subscribe: Apple Podcasts | Spotify | RSS

During Episode 25 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2025 Q1 Report: Global Trends in Biopharma

Podcast: Play in new window | Download (Duration: 12:29 — 28.6MB)

Subscribe: Apple Podcasts | Spotify | RSS

During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, explores the evolving biotech landscapes in Japan and China,

Podcast: Play in new window | Download (Duration: 13:46 — 31.5MB)

Subscribe: Apple Podcasts | Spotify | RSS

During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Year-In-Review Report: Global Trends in Biopharma

LOCUST WALK NEWS Locust Walk Acquisition Corp. Announces Pricing of Upsized $153,000,000 Initial Public Offering PHILADELPHIA and BOSTON, Jan. 7,

Transaction Case Studies MULTI-TRACK ENGAGEMENT LEADING TO AN EQUITY INVESTMENT Situation Assessment Rapid Micro Biosystems is a privately held, commercial